

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen C. D'Amico

Type or print name

Signature

May 14, 2002

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
RE APPLICATION OF  
JACKSON ET AL.

APPLICATION NO: 10/029,345

FILED: DECEMBER 20, 2001

FOR: POLYNUCLEOTIDES ENCODING NOVEL HUMAN  
PHOSPHATASES**Attention: Box Missing Parts**

Assistant Commissioner for Patents  
Washington, DC 20231

RESPONSE TO NOTICE TO FILE MISSING PARTS

Sir:

The Notice to File Missing Parts of Application - Filing Date Granted dated April 23, 2002 (a copy of which is enclosed) has a shortened statutory time set to expire on June 23, 2002.

In response, applicants now submit an original or copy of a fully executed Declaration and Power of Attorney. Please charge the \$130 surcharge fee under 37 CFR §1.16(e) to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.


Also enclosed is a paper copy of a Substitute Sequence Listing, a Substitute Computer Readable Form Copy thereof, and a Statement Verifying Identity of Above Copies.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

A duplicate copy of this letter is provided for charging purposes.

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: May 14, 2002

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen C. D'Amico  
Type or print name

  
Signature

May 14, 2002  
Date



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 10/029,345

FILED: DECEMBER 20, 2001

FOR: POLYNUCLEOTIDES ENCODING NOVEL HUMAN  
PHOSPHATASES

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING INCLUDING STATEMENT OF  
VERIFICATION IN RESPONSE TO MISSING PARTS NOTICE

Sir:

In response to the Notice to File Missing Parts of Application, the following has been amended in the Sequence Listing:

A) Lines <140> and <141> were amended to state U.S. Serial Number and filing date of Non-Provisional Application U.S. 10/029,345;

B) The features were amended for SEQ ID NO:6 and 8 to correctly define the location of the "Xaa" amino acids in each respective line <222>;

C) The Organism entries for SEQ ID NO: 179, 180, 181, 182, 183, and 193 were changed from "Artificial" to "Artificial Sequence" in each respective line <213>;

D) The "Artificial Sequence" definition for SEQ ID NO:193 was changed from "Synthesized Oligonucleotide" to "Synthesized Peptide" to accurately reflect the correct molecule type on respective line <223>; and

E) The Organism entry for SEQ ID NO:192 was changed from "Homo sapiens" to "Artificial Sequence" on line <213>, and the corresponding "Synthesized Peptide" definition was added to respective line <223> to accurately describe the molecule.

In the Sequence Listing

Support for these amendments to the Sequence Listing may be found by reference to the Specification, as originally filed, in addition to the Sequence Listing, as originally submitted.

Respectfully, no new matter has been added.

Applicants request the originally submitted paper copy and Computer Readable Form of the Sequence Listing be replaced with the paper copy and Computer Readable Form of the Substitute Sequence Listing submitted herewith. Applicants believe the Substitute Sequence Listing is in compliance with C.F.R. 1.822 and 1.823.

Applicants hereby provide a Computer Readable Form of the Substitute Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Substitute Paper Copy and the Substitute Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: May 14, 2002

  
\_\_\_\_\_  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652



MAY 17 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS

UNITED STATES PATENT AND TRADEMARK OFFICE

WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/029,345	12/20/2001	Jackson	D0072 NP

## CONFIRMATION NO. 5523

## FORMALITIES LETTER



\*OC00000007930173\*

23914  
 STEPHEN B. DAVIS  
 BRISTOL-MYERS SQUIBB COMPANY  
 PATENT DEPARTMENT  
 P O BOX 4000  
 PRINCETON, NJ 08543-4000

Date Mailed: 04/23/2002

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

Filing Date 00000009 193880 10029345

130.00 CH

## FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*

## Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.  
*A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.*
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

## Items Required To Avoid Processing Delays:

The item(s) indicated below are also required and should be submitted with any reply to this notice to avoid further processing delays.

**SUMMARY OF FEES DUE:**

Total additional fee(s) required for this application is **\$130** for a Large Entity

- **\$130** Late oath or declaration Surcharge.

---

*A copy of this notice MUST be returned with the reply.*

  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE